Compare S&P500 ETF (SPY) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? S&P500 ETF trades at $776.8 (market cap $819.04B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: S&P500 ETF is far larger — about 14.1× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 205 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SPY | TAK | |
|---|---|---|
Market Cap | $819.04B | $58.16B |
Volume | 30,746,070 | 2,467,530 |
52-Week High | $779.14 | $19.05 |
52-Week Low | $631.99 | $13.23 |
Typical Hold Time | 205 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $86.04B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day. The technical outlook is bullish, with moving averages strongly supportive and the price above key support at $775. However, oscillators are neutral, and the 6-day RSI at 75.74 suggests potential overbought conditions. A dividend of $1.89 is scheduled for payment on October 30, 2026.
The ETF's outlook remains tied to broader S&P 500 earnings, which are projected to grow 35% in 2026 but slow to 15% in 2027. Key risks include market-wide valuation concerns and potential profit growth deceleration. Investor sentiment is mixed, with some analysts highlighting defensive positioning and seasonal patterns favoring a year-end rally.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
